News
CRSP
--
0.00%
--
Here are the extremely-valued stocks Goldman Sachs is worried about
Since 1985, the median stock trading at an EV/sales ratio above 20x has decline 1% one year later, Goldman said.
CNBC.com · 3h ago
CRISPR Market Growth 2021 Along with Covid-19 Impact on Trends Analysis, Size by Analysis, Business Opportunities Outlook by Share, Forthcoming Developments till 2025 | Industry Research.co
Jan 23, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." Global “CRISPR Market” trend research...
The Express Wire · 2d ago
US Thalassemia Treatment Market Size, Share, Global Industry Analysis, Revenue, Trend And Top Growing Companies to 2027
Jan 22, 2021 (Heraldkeepers) -- Rise in number of altered Thalassemia genes, increase in awareness about the disease and high adoption of chelation therapy...
Heraldkeepers · 3d ago
mRNA Vaccines and Therapeutics Market 2020 Emerging Players, Growth Analysis And Precise Outlook – 2025
Jan 22, 2021 (Market Insight Reports) -- Global mRNA Vaccines and Therapeutics Market Size, Status And Forecast 2020-2025 Global mRNA Vaccines and...
Market Insight Reports · 3d ago
A Deep Dive into ARK ETFs
Zacks.com · 4d ago
The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Vertex Pharmaceuticals and Intellia Therapeutics
The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Vertex Pharmaceuticals and Intellia Therapeutics
Zacks · 5d ago
Genome Editing Market | 2021 Healthcare Industry Analysis by COVID-19 Impact Forecast by Size, Growth, Share Estimation, Business, and Global Trends Analysis To 2025
Jan 20, 2021 (AmericaNewsHour) -- REPORT HIGHLIGHT The Genome Editing market was valued at USD 3.98 billion by 2017, growing with 10.68% CAGR during the...
AmericaNewsHour · 5d ago
Beam, SpringWorks Biggest Gainers on BioSpace List
Beam, SpringWorks Biggest Gainers on BioSpace List, Stocks: SANA,BEAM,TSLA,EDIT,CRSP,NTLA,SWTX,PFE,TSLA,CERE,M, release date:Jan 19, 2021
GuruFocus.com · 5d ago
CRISPR (CRSP) Up More Than 80% in Past 3 Months: Here's Why
Zacks · 6d ago
Editas (EDIT) Up More Than 100% in Past 3 Months: Here's Why
Zacks · 01/18 13:41
8-K: CRISPR Therapeutics AG
Edgar Online - (EDK = 8-Ks/S1/S-4) · 01/16 03:43
Thinking about trading options or stock in Axon Enterprise, Tilray, Pfizer, Crispr Therapeutics, or General Motors?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAXN, TLRY, PFE, CRSP, and GM.
PR Newswire - PRF · 01/15 14:31
The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 14)
Benzinga · 01/15 12:57
With Rare Speed, Gene Editing Emerges as Biotech’s New Cutting Edge
Stocks of start-ups wielding tools like Crispr-Cas9 that allow companies to edit DNA and attack genetic diseases and cancer are suddenly hot. But the science is moving with incredible speed and the competition is rising.
Barrons.com · 01/14 20:11
DJ With Rare Speed, Gene Editing Emerges as Biotech's New Cutting Edge -- Barrons.com
Dow Jones · 01/14 20:11
With Rare Speed, Gene Editing Emerges as Biotechs New Cutting Edge
Stocks of start-ups wielding tools like Crispr-Cas9 that allow companies to edit DNA and attack genetic diseases and cancer are suddenly hot. But the science is moving with incredible speed and the competition is rising.
Barrons.com · 01/14 20:11
CRISPR Therapeutics Has Soared in Just a Few Weeks - What to Do Now
This is a time to nail down profits....CRSP
TheStreet.com · 01/14 18:22
5 Top-Performing ARK ETFs Worth Your Attention Now
Zacks.com · 01/13 09:20
Editas (EDIT) Gets FDA Nod to Begin Safety Study on EDIT-301
The FDA clears the initiation of the safety phase of Editas' (EDIT) early-stage study on investigational gene-editing therapy EDIT-301 for treating sickle cell disease. Shares down.
Zacks · 01/12 18:24
CRISPR and CRISPR-Associated (Cas) Genes Market Significant Demand Foreseen by 2026 | Mirus Bio LLC, Editas Medicine, Takara Bio USA
Jan 12, 2021 (Market Insight Reports) -- The " CRISPR and CRISPR-Associated (Cas) Genes – Market Development Scenario " Study has been added to HTF MI...
Market Insight Reports · 01/12 10:36
Webull provides a variety of real-time CRSP stock news. You can receive the latest news about Crispr Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About CRSP
CRISPR Therapeutics AG is a Switzerland-based gene-editing company. It focuses on the development of transformative gene-based medicines for serious diseases. The Company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform, which allows for precise directed changes to genomic deoxyribonucleic acid (DNA). The Company has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine and rare diseases. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The Company has business operations in London and the United Kingdom, as well as research and development operations in the United States.
More